GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (BSP:T1EV34) » Definitions » Capex-to-Operating-Income

Teva Pharmaceutical Industries (BSP:T1EV34) Capex-to-Operating-Income : 0.19 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Teva Pharmaceutical Industries Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Teva Pharmaceutical Industries's Capital Expenditure for the three months ended in Mar. 2024 was R$-617.50 Mil. Its Operating Income for the three months ended in Mar. 2024 was R$3,197.03 Mil.

Hence, Teva Pharmaceutical Industries's Capex-to-Operating-Income for the three months ended in Mar. 2024 was 0.19.


Teva Pharmaceutical Industries Capex-to-Operating-Income Historical Data

The historical data trend for Teva Pharmaceutical Industries's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teva Pharmaceutical Industries Capex-to-Operating-Income Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.19 0.19 0.18 0.20 0.17

Teva Pharmaceutical Industries Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.18 0.20 0.10 0.19

Competitive Comparison of Teva Pharmaceutical Industries's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Capex-to-Operating-Income falls into.



Teva Pharmaceutical Industries Capex-to-Operating-Income Calculation

Teva Pharmaceutical Industries's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-2577.295) / 15649.961
=0.16

Teva Pharmaceutical Industries's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-617.495) / 3197.032
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Teva Pharmaceutical Industries  (BSP:T1EV34) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Teva Pharmaceutical Industries Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Teva Pharmaceutical Industries (BSP:T1EV34) Business Description

Address
124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.

Teva Pharmaceutical Industries (BSP:T1EV34) Headlines

No Headlines